Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has advanced its cancer treatment portfolio, striking its most significant deal yet with MSD to launch a Phase III trial for eftilagimod alfa in treating non-small cell lung cancer. The company reported positive results from multiple clinical trials, including promising outcomes in head and neck cancer, and has secured a substantial A$100.2 million financing, extending its cash runway to the end of 2026. Immutep’s innovations also extend to a first-in-class LAG-3 agonist antibody for autoimmune diseases and a novel oral anti-LAG-3 therapy for cancer, developed in collaboration with Cardiff University.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
